An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01202227
First received: August 31, 2010
Last updated: April 5, 2013
Last verified: April 2013
  Purpose

The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain).


Condition Intervention Phase
Spinal Cord Diseases
Spinal Cord Injuries
Neuralgia
Pain
Drug: pregabalin
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Number of Participants With Peripheral Edema [ Time Frame: Baseline, Weeks 4, 20, 36, 52, and 53 ] [ Designated as safety issue: Yes ]
    Number of participants who had peripheral edema in lower extremities. Edema was categorized as follows: trace, pitting 1 (lower leg), 2 (lower leg to knee), and 3 (above knee and /or presacral edema).

  • Number of Participants With Facial/Periorbital Edema [ Time Frame: Baseline, Weeks 4, 20, 36, 52, and 53 ] [ Designated as safety issue: Yes ]
    Number of participants who had facial or periorbital edema.

  • Number of Participants With Generalized or Abdominal Edema [ Time Frame: Baseline, Weeks 4, 20, 36, 52, and 53 ] [ Designated as safety issue: Yes ]
    Number of participants who had generalized or abdominal edema.

  • Number of Participants With Localized Pain Related to Deep Vein Thrombosis (DVT) [ Time Frame: Baseline, Weeks 4, 20, 36, 52, and 53 ] [ Designated as safety issue: Yes ]
    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

  • Number of Participants With Localized Tenderness Related to Deep Vein Thrombosis (DVT) [ Time Frame: Baseline, Weeks 4, 20, 36, 52, and 53 ] [ Designated as safety issue: Yes ]
    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

  • Number of Participants With Swelling Related to Deep Vein Thrombosis (DVT) [ Time Frame: Baseline, Weeks 4, 20, 36, 52, and 53 ] [ Designated as safety issue: Yes ]
    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

  • Number of Participants With Pitting Edema Related to Deep Vein Thrombosis (DVT) [ Time Frame: Baseline, Weeks 4, 20, 36, 52, and 53 ] [ Designated as safety issue: Yes ]
    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

  • Number of Participants With Collateral Superficial Veins (Non-varicose) Related to Deep Vein Thrombosis (DVT) [ Time Frame: Baseline, Weeks 4, 20, 36, 52, and 53 ] [ Designated as safety issue: Yes ]
    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

  • Number of Participants With Skin Redness Related to Deep Vein Thrombosis (DVT) [ Time Frame: Baseline, Weeks 4, 20, 36, 52, and 53 ] [ Designated as safety issue: Yes ]
    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

  • Number of Participants With Visual Field Deteriorated [ Time Frame: 53 weeks ] [ Designated as safety issue: Yes ]
    Number of participants who had normal visual field at baseline and showed abnormal result after the study treatment, assessed by confrontational visual field test (neurological examination).

  • Number of Participants With Deterioration in Neurological Examination Findings [ Time Frame: 53 weeks ] [ Designated as safety issue: Yes ]
    Worsening of the condition relative to baseline was reported as deteriorated. Assessment categories are as follows: normal or abnormal for Cranial Nerve Function, Mental State, and Coordination; normal, mild, moderate, or severe ataxia for Gait; none/absent, normal, or hyper-reflexic for Deep Tendon Reflexes; absent or present for Abnormal Reflexes; normal, mild, moderate, or severe weakness for Muscle Strength; slight, more marked, or considerable increase, or affected parts rigid in flexion or extension for Muscle Tone; absent or present for Sensory Function.

  • Number of Participants With Suicidal Ideation According to Sheehan Suicidality Tracking Scale (Sheehan-STS) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52 ] [ Designated as safety issue: Yes ]
    The Sheehan-STS is an 8-item prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Participants who reported a score of ≥1 (5-point scale ranging from 0: not at all to 4: extremely) for Item 2, 3, 4 or 5 of the Sheehan-STS prognostic scale is considered to have suicidal ideation as the scores are mapped to Category 4 (suicide ideation) of the Columbia Classification Algorithm of Suicide Assessment.


Secondary Outcome Measures:
  • Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Total Scores [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52 ] [ Designated as safety issue: No ]

    The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.

    Range: 0 to 45 for total score. Change = observation mean minus baseline mean. Negative change indicated improvement.


  • Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Sensory Scores [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52 ] [ Designated as safety issue: No ]

    The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.

    Range: 0 to 33 for sensory score. Change = observation mean minus baseline mean. Negative change indicated improvement.


  • Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Affective Scores [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52 ] [ Designated as safety issue: No ]

    The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.

    Range: 0 to 12 for affective score. Change = observation mean minus baseline mean. Negative change indicated improvement.


  • Change From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score [ Time Frame: Baseline, Week 52 ] [ Designated as safety issue: No ]

    The mBPI-10 is a self administered questionnaire that assesses pain interference with functional activities over the past week. These items are measured on an 11 point scale, ranging from "does not interfere" (0) to "completely interferes" (10). A composite score, the Pain Interference Index, will be calculated by averaging the 10 items that comprise the scale.

    Change = observation mean at Week 52 minus baseline mean.



Enrollment: 104
Study Start Date: September 2010
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pregabalin
Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period
Drug: pregabalin
Pregabalin capsules taken twice a daily (150-600mg/day)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Inclusion criteria for subjects to be shifted from Study A0081107

  • Subjects who completed the 18-week study period in Study A0081107 conducted for chronic neuropathic pain after spinal cord injury;
  • Subjects who completed assessments of all efficacy endpoints until the end of the treatment phase of the preceding Study A0081107 (V7);

Inclusion criteria for subjects to be new participants in this study

  • Subjects with central neuropathic pain after stroke or multiple sclerosis;
  • At least 6 months have passed after the onset of central neuropathic pain;
  • Pain VAS at least 40mm in Visit 1 and Visit 2;

Exclusion Criteria:

  • Creatinine clearance < 60 mL/min;
  • Platelet count < 100 × 103/mm3 ; White blood cell (WBC) count < 2500 / mm3; Neutrophil count < 1500/ mm3;
  • Subjects who are expected to require surgery during the trial;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01202227

Locations
Japan
Kimura Clinic
Nagoya, Aichi, Japan
Chubu Rosai Hospital
Nagoya, Aichi, Japan
Nagoya Kyoritsu Clinic
Nagoya, Aichi, Japan
Senboku Kumiai General Hospital
Daisen, Akita, Japan
Go neurosurgical clinic
Chikushi-gun, Fukuoka, Japan
Spinal Injuries Center
Iizuka, Fukuoka, Japan
Brain Attack Center Ota Memorial Hospital
Fukuyama, Hiroshima, Japan
Hokkaido Chuo Rosai Hospital Sekison Center
Bibai, Hokkaido, Japan
Hakodate Central General Hospital
Hakodate, Hokkaido, Japan
Kobe Tokushukai Hospital
Kobe, Hyogo, Japan
Aida Kinen Rehabilitation Hospital
Moriya, Ibaraki, Japan
General Hanamaki Hospital
Hanamaki, Iwate, Japan
Uchida Rehabilitation Orthopedic Clinic
Kawasaki, Kanagawa, Japan
Kumamoto Rehabilitation Hospital
Kikuchi-gun, Kumamoto, Japan
Kohnan Hospital
Sendai, Miyagi, Japan
Sendai Pain Clinic
Sendai-city, Miyagi, Japan
National Hospital Organization Niigata National Hospital
Kashiwazaki, Niigata, Japan
Nakamura Hospital
Beppu, Oita, Japan
Kitasato University Kitasato Institute Medical Center Hospital
Kitamoto, Saitama, Japan
Kamitsuga General Hospital
Kanuma, Tochigi, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
Jukoukai hospital
Koto-ku, Tokyo, Japan
National Hospital Organization, Murayama Medical Center
Musashimurayama-shi, Tokyo, Japan
Okitama Public General Hospital
Higashiokitama-gun, Yamagata, Japan
Tokushima University Hospital
Tokushima, Japan
National Hospital Organization Yamagata Hospital
Yamagata, Japan
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01202227     History of Changes
Other Study ID Numbers: A0081252
Study First Received: August 31, 2010
Results First Received: January 10, 2013
Last Updated: April 5, 2013
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Pfizer:
Central Nervous System Diseases
Therapeutic Uses
Wounds and Injuries
Trauma
Nervous System
pregabalin

Additional relevant MeSH terms:
Spinal Cord Diseases
Spinal Cord Injuries
Neuralgia
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Pain
Neurologic Manifestations
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Pregabalin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on September 18, 2014